Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model
Blood (2009) 114 (26): 5322–5330.
Currently there are no citedby results. Try again later.
